Go back to News
NEWS
GA_P advises Uriach on the minority investment in ICG and the acquisition of French group Laboratories Ineldea
15 November, 2023
AGómez-Acebo & Pombo has advised Grupo J. Uriach, a Catalan company specialising in the Natural Consumer Healthcare sector, on the entry of the private equity fund ICG in its share capital and on the simultaneous acquisition of the French group Laboratories Ineldea.
With this acquisition, Grupo J. Uriach aims to have a turnover of 450 million euros by 2025, in addition to consolidating its leadership in the Natural Consumer Healthcare business in Europe and strengthening its position in the countries where it already operates, consolidating more powerful local businesses.
The closing of both transactions is subject, among others, to regulatory approvals.
The GA_P team has been led by Daniel Marín, Carolina Posse and Beatriz Dosdá, partner and associates of Corporate, together with Zina Safer, head of the legal department of Grupo J. Uriach. Uriach Group. The transaction has also been advised by Iñigo Igartua, Andrea Díez de Uré and Jesús Urriza, partner and associates of Competition, and Rafael Aguilera and Iñigo Arrieta, partner and associates of Banking.
Read full article
With this acquisition, Grupo J. Uriach aims to have a turnover of 450 million euros by 2025, in addition to consolidating its leadership in the Natural Consumer Healthcare business in Europe and strengthening its position in the countries where it already operates, consolidating more powerful local businesses.
The closing of both transactions is subject, among others, to regulatory approvals.
The GA_P team has been led by Daniel Marín, Carolina Posse and Beatriz Dosdá, partner and associates of Corporate, together with Zina Safer, head of the legal department of Grupo J. Uriach. Uriach Group. The transaction has also been advised by Iñigo Igartua, Andrea Díez de Uré and Jesús Urriza, partner and associates of Competition, and Rafael Aguilera and Iñigo Arrieta, partner and associates of Banking.
Read full article
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
¡NEW! 
PUBLICATION
¡NEW!
Pharma & Healthcare No. 48
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
¡NEW! 
PUBLICATION
21 Apr, 2026
The 28th Corporate Regime: the EU Inc.
The Proposal for a Regulation of the European Parliament and of the Council on the 28th Regime Corporate Legal Framework – ‘EU Inc.’, dated 18 March 2026, introduces a new form of European private limited company. Originally envisaged for start-ups and scale-ups, it has been decided to allow its adoption by all companies. There is no minimum share capital requirement; shares may have no nominal value and may carry multiple voting rights, among other features. The Commission is expected to approve model articles of association so that a company can be incorporated online in less than forty-eight hours and for less than one hundred euros.
21 Apr, 2026
PUBLICATION
17 Apr, 2026
Can a framework agreement lacking an exclusivity or minimum orders clause be discharged by breach?
All cases decided by the Supreme Court and their specific details are discussed. There is no single solution to the problem of terminating a framework supply of services agreement without an exclusivity clause or a minimum purchases obligation.
17 Apr, 2026
PUBLICATION
12 Mar, 2026
European reform of the sustainability reporting regime under Directive (EU) 2026/470: consequences of its non-transposition into domestic law
Directive (EU) 2026/470 (Omnibus I) has been published, limiting the obligation to prepare a sustainability report to public-interest entities with more than 1,000 employees and a net turnover of more than €450 million during the preceding financial year, as well as to parent companies of a large group that exceed these figures on a consolidated basis. The Directive amends the audit directive, the accounting directive, the corporate sustainability reporting directive (CSRD) and the corporate sustainability due diligence directive (CSDDD).
12 Mar, 2026
PUBLICATION
11 Mar, 2026
Uncertificated share pledge creation, enforceability and avoidance (Supreme Court Judgment no.183/2026 of 10 February)
In Judgment no. 183/2026, of 10 February, the Supreme Court analysed the requirements for the validity and enforceability of an uncertificated registered share pledge and examined the conditions for its avoidance in the context of insolvency proceedings.
11 Mar, 2026
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICATION
09 Feb, 2026
Notarial enforcement of pledges. Is Article 1872 of the Civil Code mandatory? In what sense?
The clause agreed upon must comply, for greater certainty, with the provisions of the new judicial enforcement procedure. It will be necessary to agree on an appraised value, which is not required in Article 1872 CC, because otherwise the award would be similar to a ‘forfeiture proviso’ (pactum commissorium), which the Civil Code neutralised with the drastic imposition of extinguishment of the debt in its entirety.
09 Feb, 2026
PUBLICATION
06 Feb, 2026
Automotive and Sustainable Mobility No. 29
Summary of legislative and jurisprudential developments relating to the automotive sector.
06 Feb, 2026
PUBLICATION
15 Dec, 2025
Direct harm due to de facto expulsion: Article 241 of the Companies Act (Supreme Court Judgment, First Chamber, 22 October 2025)
This paper analyses the subject matter scope of application of a ‘director liability to shareholder claim’ (claim for payment of damages filed by a shareholder against a company director). Although, as a general rule, shareholders cannot claim compensation for the harm caused to their share in a company’s estate, compensation for de facto expulsions or harm to liquidating dividends may be awarded through a director liability to shareholder claim.
15 Dec, 2025